

Anti-tumor activity of plant extracts against human breast cancer cells are different in monolayer and three-dimensional cell culture screening models: A comparison on 34 extracts

Nhan Lu-Chinh Phan^{1,2}, Khuong Duy Pham^{2,3}, Mai Thi-Thanh Nguyen^{2,4}, Ngoc Phan Kim^{2,3}, Kiet Dinh Truong⁵, Phuc Van Pham^{1,2,3,6,*}



Use your smartphone to scan this QR code and download this article

¹Stem Cell Institute, University of Science, Ho Chi Minh City, Viet Nam

²Viet Nam National University Ho Chi Minh City, Viet Nam

³Laboratory of Stem Cell Research and Application, University of Science, Ho Chi Minh City, Viet Nam

⁴Faculty of Chemistry, University of Science, Ho Chi Minh City, Viet Nam

⁵Medical Genetics Institute, Ho Chi Minh City, Viet Nam

⁶Cancer Research Laboratory, University of Science, Ho Chi Minh City, Viet Nam

Correspondence

Phuc Van Pham, Stem Cell Institute, University of Science, Ho Chi Minh City, Viet Nam

Viet Nam National University Ho Chi Minh City, Viet Nam

Laboratory of Stem Cell Research and Application, University of Science, Ho Chi Minh City, Viet Nam

Cancer Research Laboratory, University of Science, Ho Chi Minh City, Viet Nam

Email: pvphuc@hcmuns.edu.vn; phucpham@sci.edu.vn

History

- Received: 2019-11-25
- Accepted: 2020-02-22
- Published: 2020-03-22

DOI : 10.15419/bmrat.v7i3.593



Check for updates

Copyright

© Biomedpress. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.



ABSTRACT

Introduction: The monolayer cell culture model is a popular model for screening anti-tumor activity of plant extracts. However, almost the extracts selected for screening in this model have failed in subsequent animal models. Therefore, there is only about 5 % of candidates from the original thousands of drugs that are screened which ultimately reach clinical trial. This study aimed to compare the differences in anti-tumor activity of 34 plant extracts against breast cancer cells in 2 models of monolayer cell culture (2D) and in three-dimensional (3D) cell culture. **Methods:** Four breast cancer cell lines (MCF-7, CD44⁺CD24⁻ MCF-7, VN9, and CD44⁺CD24⁻VN9) were used to generate the 2D and 3D models (the 3D model was developed by culturing breast cancer cells in matrigel). The extracts were got from the plant extract library that prepared in the previous study. The anti-tumor activity was evaluated via half inhibitory concentrations (IC₅₀ values). **Results:** Of the 34 extracts, E12, E7, E5 and E6 of them had an effect on MCF-7, CD44⁺CD24⁻ MCF-7, VN9 and CD44⁺CD24⁻VN9 cells, respectively. The results indicated 10 potentially strong candidates for future drug development targeting hypoxic areas in breast cancer. **Conclusion:** The 3D culture model exhibited higher resistance to extracts than the 2D culture model. The CD44⁺CD24⁻ cell population of both VN9 and MCF-7 cell lines showed higher drug resistance than the original cell lines (VN9 and MCF-7).

Key words: breast cancer, drug screening, natural extract, CD44+CD24-

INTRODUCTION

For the discovery of new drugs, screening of natural compounds that target the proliferation of cancer cells is important¹. For libraries with hundreds to thousands of extracts, they need to be screened with high-performance screening methods. Such methods allow the screening of many compounds at different concentrations at the same time on each target cell or the combination of compounds- with uniformity and high accuracy^{2,3}.

Screening of extracts on cancer cell models in 2-dimensional (2D) monolayer culture is limited because the monolayer model lacks the tumor cell characteristics of physiological tumors in the body⁴. Meanwhile, screening done on a cancer model in 3-dimensional (3D) culture may be better for studying drug effects since the 3D culture model is more similar to the *in vivo* animal models (and possibly clinical trials); the 3D model more closely reflects characteristics of *in vivo* tumors, such as differentiation, tumor microenvironment, and distribution of hypoxia in certain populations⁵⁻⁷. Many methods have been developed to create 3D cells like tumors in the body;

these methods include use of U-shaped bottom well, the hanging drop, and cell growth in bio-matrix^{6,8}.

The method of using a U-shaped bottom well is heavily used in 3D cell model studies. However, one downside is that not all cell types can develop into 3D cell mass by this method⁹. For hanging drop culture, the advantage is that gravity is used to precipitate the cells together and thereby stimulate the cells to stick together into 3D spheres¹⁰. This method has a disadvantage of using very gentle manipulations and is difficult to develop if screened at high throughput automation. Meanwhile, the method of using biological substrates (like Matrigel) offers great potential for the development of 3D cell model¹¹⁻¹³. Matrigel is usually stored in frozen form, at a concentration of 10-15 mg/mL; it is thawed at 4 °C and gelled in a temperature range of 24-37 °C for 30 minutes. Matrigel promotes the differentiation of different cell lines (e.g. prostate, salivary gland, mammary epithelium, pancreas, Schwann cells, intestinal cells, and bone cells), of primary cell lines (e.g. sertoli cells, blood cells, cartilage cells, epithelial cells, endometrial cells, and fallopian epithelial cells), and even tissue explants (e.g.

Cite this article : Lu-Chinh Phan N, Duy Pham K, Thi-Thanh Nguyen M, Phan Kim N, Dinh Truong K, Van Pham P. **Anti-tumor activity of plant extracts against human breast cancer cells are different in monolayer and three-dimensional cell culture screening models: A comparison on 34 extracts.** *Biomed. Res. Ther.*; 7(3):3667-3677.

neural crest, immature follicles, and zygote)¹⁴.

This study used matrigel to create a 3D cell model of breast cancer for the purpose of screening natural compounds that inhibit the growth of breast cancer cell. Modeling of 2D and 3D monolayer cancer cells was carried out in parallel (simultaneously) with the same evaluation agents, including Alarma Blue. The IC₅₀ (half maximal inhibitory concentration) values were compared between 2D and 3D cancer cell models to evaluate and select the extract which showed different effects in these two models.

This study used 34 natural plant extracts and two control drugs (Doxorubicin and Tiparazamine) on 4 cell lines (MCF-7, CD44⁺CD24⁻ MCF-7, VN9, and CD44⁺CD24⁻ VN9 cells).

METHODS

Cell lines

MCF-7 cell line was obtained from ATCC (Manassas, VA). VN9 cell line was obtained from the Stem Cell Institute, University of Science, VNU-HCM. MCF-7 and VN9 cells were cultured in DMEM/F12 (Sigma-Aldrich, St Louis, MO), 10% fetal bovine serum (FBS) (Sigma-Aldrich, St. Louis, MO), 1% antibiotic-antimycotic (Sigma-Aldrich, St Louis, MO). The CD44⁺CD24⁻ cells were sorted from VN9 cells (and termed CD44⁺CD24⁻ VN9) or from MCF-7 (and termed CD44⁺CD24⁻ MCF-7) by magnetic-activated cell sorting (MACS; Miltenyi Biotec, Bergisch Gladbach, Germany), and then expanded in M171 medium (Thermo Fisher Scientific, Waltham, MA) with MEGS Supplement (Thermo Fisher Scientific, Waltham, MA) for maintenance of stemness. The CD44⁺CD24⁻ populations corresponded to the cancer stem cell (CSC) populations.

Chemicals

In the research study, the library of the 34 extract (Table 1), which were coded with 'E' as the initial label (i.e. E1-E34), were obtained from the Division of Medicinal Chemistry, Faculty of Chemistry, University of Science, Vietnam National University Ho Chi Minh City, Vietnam. Doxorubicin hydrochloride and tirapazamine were purchased from Sigma-Aldrich.

Cell culture in monolayer (2D) and three-dimensional (3D) culture

For 2D models, single cells (MCF-7, CD44⁺CD24⁻ MCF-7, VN9 or CD44⁺CD24⁻ VN-9) were harvested and seeded in 96-well plates at a final density of 1000 cells per well, and grown for 5 days. Fresh medium was replenished every two

days. Cancer cells were cultured in DMEM/F12, 10% FBS (Sigma-Aldrich), and 1% antibiotic-antimycotic (Sigma-Aldrich). CD44⁺CD24⁻ cancer cells were cultured in M171 medium (Thermo Fisher Scientific) with MEGS supplement (Thermo Fisher Scientific). For the 3D model, 5 μ L of 1000 single cells was mixed with 5 μ L of matrigel (Sigma-Aldrich) on ice and placed on the edge of the well. The plate was incubated at 37 °C in 10 minutes for gel polymerization, and then 100 μ L of pre-warmed medium was added on top of the gel. The pre-warmed medium was a requisite for manipulation of 3D culture to avoid melting the gel (Figure 1).

Cell viability assay and IC₅₀ determination

After 5 days of culture, the cells and organoids were treated for 48 hours with the respective 34 extracts at the following concentrations: 31.25 μ g/ml, 62.5 μ g/ml, 125 μ g/ml, 250 μ g/ml, 500 μ g/ml, or 1000 μ g/ml. The concentrations of doxorubicin evaluated were: 62.5 nM, 125 nM, 250 nM, 500 nM, and 2000 nM; the concentrations of tirapazamine evaluated were: 15.625 μ M, 31.25 μ M, 62.5 μ M, 125 μ M, 250 μ M, and 500 μ M. Then, Alarma Blue (Sigma-Aldrich) was added to the wells at a final concentration of 10 μ g/mL and incubated in the dark for 1 hour. The fluorescence intensity was read using an DTX880 system (Beckman Coulter, Brea, CA) at excitation wavelength of 535 nm, emission wavelength of 595 nm, and integration time of 500 μ s. The data were normalized to control values (untreated wells) and IC₅₀ values were calculated with GraphPad Prism 7 (GraphPad Software, Inc., La Jolla, CA).

Statistical analysis

All experiments were performed in triplicate. Statistical significance was set at $P < 0.05$. Data were analyzed by GraphPad Prism 7.

RESULTS

IC₅₀ values of extracts are different on MCF-7 2D and 3D models

The IC₅₀ results of doxorubicin and tirapazamine showed that both 2D and 3D models were successfully established for anti-tumor activity evaluation (Table 2). The IC₅₀ results of the 34 plant extracts on MCF-7 breast cancer cells in 2D and 3D models are summarized in Table 3.

There were 12/34 extracts which showed effects on both 2D and 3D culture models. These 12 extracts were: E4, E10, E11, E12, E17, E18, E20, E21, E22, E27,

Table 1: List of 34 natural extracts used in this study

Code of extract	Plant (solvent)	Code of extract	Plant (solvent)
E4	<i>Buchanania Latifolia</i> – (CH ₃ OH)	E26	<i>Anisoptera costata</i> – (CH ₃ OH)
E7	<i>M. Camptosperma</i> – (CH ₃ OH)	E27	<i>Anisoptera costata</i> – (CH ₃ OH)
E8	<i>D. Dyeri</i> – (CH ₃ OH)	E28	<i>Willughbeia cochinchinensis</i> – (CH ₃ OH)
E9	<i>H. recopei</i> – (CH ₃ OH)	E30	<i>Streblus ilicifolius</i> – (CH ₃ OH)
E10	<i>H. recopei</i> – (CH ₃ OH)	E31	<i>B. pandurate</i> – (CH ₃ OH)
E11	<i>S. thorelii</i> – (CH ₃ OH)	E32	<i>Paramignya trimera</i> – (CH ₃ OH)
E12	<i>S. thorelii</i> – (CH ₃ OH)	E35	<i>Mangifera mekongiensis</i> – (CH ₃ OH)
E13	<i>D. turbinatus</i> – (CH ₃ OH)	E36	<i>Embelia ribes</i> – (CH ₃ OH)
E14	<i>D. turbinatus</i> – (CH ₃ OH)	E37	<i>Willughbeia cochinchinensis</i> – (C ₄ H ₈ O ₂)
E15	<i>D. costatus</i> – (CH ₃ OH)	E38	<i>Artocarpus heterophyllus</i> – (C ₄ H ₈ O ₂)
E16	<i>D. costatus</i> – (CH ₃ OH)	E39	<i>Mangifera mekongiensis</i> – (C ₄ H ₈ O ₂)
E17	<i>Hopea odorata</i> – (CH ₃ OH)	E40	<i>Taxus wallichiana</i> – (CH ₂ Cl ₂)
E19	<i>Vatica odorata</i> – (CH ₃ OH)	E41	<i>Caesalpinia sappan</i> – (CH ₂ Cl ₂)
E20	<i>Vatica odorata</i> – (CH ₃ OH)	E42	<i>Trigona minor</i> – (Hexan)
E21	<i>Dipterocarpus alatus</i> – (CH ₃ OH)	E43	<i>B. pandurate</i> – (Chloroform)
E22	<i>Shorea roxburghii</i> – (CH ₃ OH)	E45	<i>Swintonia floribunda</i> – (CH ₃ OH)
E25	<i>K. laurifolia</i> – (CH ₃ OH)	E46	<i>Mangifera reba Pierre 1897</i> – (CH ₃ OH)




Figure 1: The 3D cell culture method using matrigel. The matrigel and the cells were seeded with a density of 1000 cells/well. The matrigel was established on the edge of the well after 30 mins in 37 °C which has a crescent shape. After 5 days in progress, the drug testing process was performed in 48 hours.

Table 2: The IC₅₀ of doxorubicin and tirapazamin on cell lines

Cell lines	Models	IC ₅₀ DOX (ng/mL)	IC ₅₀ TPZ (µg/mL)
VN9	2D	1476	292
	3D	1868	128
CD44 ⁺ CD24 ⁻ VN9	2D	98.52	315.2
	3D	1711	105.4
MCF-7	2D	1674	159.4
	3D	2354	68.14
CD44 ⁺ CD24 ⁻ MCF-7	2D	278.3	174.9
	3D	3131	147

Abbreviations: DOX: doxorubicin, TPZ: tirapazamin, IC₅₀: half inhibitory concentration

Table 3: The IC₅₀ values of 34 extracts on MCF-7 breast cancer cell line

Extracts	IC ₅₀ values (µg/mL)		Extracts	IC ₅₀ values (µg/mL)	
	2D model	3D model		2D model	3D model
E4	187.5	383.7	E25	597.4	870.8
E7	248.2	332.8	E27	165.3	242.5
E8	478.7	533.1	E28	299.7	673.3
E9	701.4	653.5	E30	1476	794
E10	310	154.7	E31	257.3	308.5
E11	342.9	198.3	E32	235.2	225.1
E12	303.5	160.4	E35	4450	615.9
E13	1779	1061	E36	2187	575.5
E14	348.6	593	E37	326.1	308.8
E15	1106	639.8	E38	368.1	692.2
E16	316.8	361.9	E39	345.6	270.6
E17	159.4	232.4	E40	70	1419
E18	112.4	230	E41	526.2	2063
E19	489.5	621.8	E42	499.7	359.6
E20	86.42	168.4	E43	306	620.4
E21	57.67	71.97	E45	155	361.9
E22	83.58	87.92	E46	135.4	387.6

Table 4: The IC₅₀ values of 34 extracts on CD44⁺CD24⁻ MCF-7 breast cancer cell line

Extracts	IC ₅₀ values (μg/mL)		Extracts	IC ₅₀ values (μg/mL)	
	2D model	3D model		2D model	3D model
E4	66.2	360.3	E25	173.6	587.8
E7	69.42	307.7	E27	80.45	214.1
E8	103.2	937.8	E28	134.9	481.6
E9	153	887.8	E30	508.4	935.9
E10	50.48	162.2	EE31	85.04	253.5
E11	58.14	217.5	E32	56.65	223
E12	61.95	162	E35	73.95	624.6
E13	262.4	1243	E36	507	1215
E14	74.52	375.2	E37	103.5	322.7
E15	258.3	699.7	E38	229.8	980.4
E16	70.91	146.4	E39	62.65	386.6
E17	20.31	56.97	E40	274.5	1648
E18	145	39.89	E41	303.3	1257
E19	31.88	227.4	E42	102.3	293.9
E20	35.6	89.56	E43	60.97	449.6
E21	26.71	252.9	E45	32.16	295.5
E22	809.5	110.4	E46	71.98	459.6

Abbreviation: IC₅₀: half inhibitory concentration

E45, and E46. However, most of the extracts predominantly had effects on the 2D model. In fact, 27 extracts on the 3D models were correlated with increased resistance by the cancer cells as compared to the resistance on the 2D models. Specifically, there were 7 extracts that had an IC₅₀ values in the 3D model which were lower than in the 2D culture model. The 7 extracts were: E10, E12, E15, E30, E35, E36, and E42 (Figure 2). Thus, they are potential candidates for further use in the 3D culture model of MCF-7 breast cancer.

The results of hit extracts on CD44⁺CD24⁻ MCF-7 in 2D and 3D models

There were 7/34 extracts that had effects on both 2D and 3D culture models. These 7 extracts were: E7, E10, E12, E17, E18, E19, E21, and E45. However, the majority of the extracts predominantly showed effects on the 2D model (Table 5). As seen in Table 5, cells grown in the 3D model showed more resistance to the effects of the 32 extracts than the cells grown in the 2D model. In particular, there were 2 extracts which had IC₅₀ values in the 3D model that were lower than

the values in the 2D model; those 2 extracts were E26 and E22 (Figure 3). Therefore, they are potential candidates for further research in the 3D culture model of the MCF-7 breast cancer stem cell (CSC). Comparing with the results on the MCF-7 cell line, it was observed that the CD44⁺CD24⁻ sub-population of MCF-7 cells has a much higher resistance to the same extracts tested.

The results of hit extracts on VN9 cultured in 2D and 3D models

There were 5/34 extracts which showed effects on both 2D and 3D culture models. The 5 extracts were: E4, E7, E20, E21, and E45. However, most of the extracts had predominant effects on the 2D models (Table 6). As Table 6 demonstrates, 29 extracts on the 3D models were correlated with increased resistance by the cancer cells, as compared to their resistance on the 2D models. In particular, 5 extracts had IC₅₀ values in the 3D model that were lower than the values in the 2D model. The 5 extracts were: E15, E18, E22, E25 and E30 (Figure 4). Therefore, these are potential

Table 5: Summary of hit extracts on each cell types and models

Cells	2D model	3D model	The extracts more sensitive on 3D than 2D
MCF-7	E20, E21, E22, E40	-	E10, E12, E15, E30, E35, E36, E42
CD44 ⁺ CD24 ⁻ MCF-7	E4, E7, E10, E11, E12, E14, E16, E17, E19, E20, E21, E27, E31, E32, E35, E39, E43, E45, E46	E17, E18, E20	E26, E22
VN9	-	-	E15, E18, E22, E30
CD44 ⁺ CD24 ⁻ VN9	E4, E7, E10, E11, E12, E14, E16, E17, E19, E20, E21, E31, E32, E35, E39, E45	E7, E21	E18, E22

Table 6: The IC₅₀ values of 34 extracts on VN9 breast cancer cell line

Extracts	IC ₅₀ values (µg/mL)		Extracts	IC ₅₀ values (µg/mL)	
	2D model	3D model		2D model	3D model
E4	238.9	518.2	E25	4681	722.9
E7	345.6	297	E27	497.8	345.1
E8	1287	588.2	E28	1806	613.5
E9	916.8	535.7	E30	4976	1568
E10	712.6	270.9	E31	293.5	463.9
E11	559.2	686.4	E32	403.6	347
E12	635.9	496.2	E35	5799	3004
E13	7756	2706	E36	7437	3605
E14	531.4	638.3	E37	559.3	977.5
E15	5744	1088	E38	3158	2260
E16	377.7	987.1	E39	697.3	847.6
E17	211	431	E40	267.2	1212
E18	2055	430.6	E41	1083	871.1
E19	357.5	654	E42	2136	963.8
E20	103.8	122.6	E43	247.5	504.1
E21	304.2	146.1	E45	196.1	262
E22	2964	324.1	E46	1080	417.3

Abbreviation: IC₅₀: half inhibitory concentration




Figure 2: Comparing the IC₅₀ values of 34 extracts, doxorubicin and tirapazamine on MCF-7 breast cancer cell line. Scale 1: Red corresponds to sensitivity, green corresponds to high resistance. **Scale 2:** Black corresponds to, ratio of 2D/3D concentration is greater than 1. Gray white corresponds to, ratio of 2D/3D concentration is less than 1. **Abbreviations:** TPZ: tirapazamine, 2D: mononuclear cell culture, 3D: three-dimensional cell culture model, IC₅₀: half inhibitory concentration




Figure 3: Comparing the IC₅₀ values of 34 extracts, Dox and TPZ on CD44⁺CD24⁻ MCF-7 breast cancer cell line. Scale 1: Red corresponds to sensitivity, green corresponds to high resistance. **Scale 2:** Black corresponds to ratio of 2D/3D concentration is greater than 1. Gray white corresponds to ratio of 2D/3D concentration is less than 1. **Abbreviations:** Dox: doxorubicin, TPZ: tirapazamine, 2D: mononuclear cell culture, 3D: three-dimensional cell culture model




Figure 4: Comparing the IC₅₀ values of 34 extracts, Dox and TPZ on VN9 breast cancer cell line. Scale 1: Red corresponds to sensitivity, green corresponds to high resistance. Scale 2: Black corresponds to ratio of 2D/3D concentration is greater than 1. Gray white corresponds to ratio of 2D/3D concentration is less than 1. **Abbreviations:** Dox: doxorubicin, TPZ: tirapazamine, 2D: mononuclear cell culture, 3D: three-dimensional cell culture model




Figure 5: Comparing the IC₅₀ values of 34 extracts, Dox and TPZ on CD44⁺CD24⁻ VN9 breast cancer cell line. Scale 1: Red corresponds to sensitivity, green corresponds to high resistance. Scale 2: Black corresponds to ratio of 2D/3D concentration is greater than 1. Gray white corresponds to ratio of 2D/3D concentration is less than 1. **Abbreviations:** Dox: doxorubicin, TPZ: tirapazamine, 2D: mononuclear cell culture, 3D: three-dimensional cell culture model

candidates for further studies in the 3D culture model of VN9 breast cancer.

Results of hit extracts on CD44⁺CD24⁻ VN9 cultured in 2D and 3D

There were 6/34 extracts affected both the 2D and 3D culture models: E4, E7, E10, E12, E18, and E45. Most of the extracts, however, mainly affected the 2D models (Table 7). As shown in Table 7, 32 extracts on the 3D models were correlated with increased resistance by the cancer cells, as compared to their resistance on the 2D models. In particular, there were 2 extracts which had IC₅₀ values in the 3D model that were lower than those in the 2D culture model; these extracts were E18 and E22 (Figure 5). Thus, they are potential candidates for further studies in the 3D VN9 breast CSC model. Comparison of screening results of VN9 with CD44⁺CD24⁻ phenotype versus the original VN9 demonstrated that the CSC cell line (CD44⁺CD24⁻ VN9) was more resistant to the extracts in the 3D culture model. Therefore, in this study, the number of extracts tested that showed an effect on this cell line was 2, indicating that VN9 CSC can carry more resistant characteristics than normal cells.

DISCUSSION

The use of bio-matrix substrates (such as matrigel) to create 3D culture models is very convenient for drug screening. Use of a gel forming method that contains the cells on the side of the culture well in a 96-well plate facilitates easy manipulation without disrupting the gel structure or limiting cell growth in the form of single layer in the center of the well. This method also allows the creation of a 3D cell mass with a size of 100 μm within 5 days of culture. The drug test is conducted in 48 hours such that the entire drug testing procedure can be summarized in 7 days. In order to minimize errors when comparing 2D and 3D models, we conducted all experiments with both models in parallel. For both 2D and 3D models, the threshold of extracting effect was lower than 200 μg/mL.

A number of published studies have shown that 3D breast cell culture better reflects the histological, biological, and molecular features of primary tumors than the same cells cultured using traditional 2D techniques¹⁵. In a study by Imamura *et al.*, on a 3D breast cancer model, the breast cell mass was found to have the presence of a hypoxic cell population⁷; it is for this reason that the cell mass becomes sensitive to tiparazamine. In our study, we show that 10 extracts have the same effect as tiparazamine on breast cancer

cells, and that they might be suitable candidates for hypoxia-targeted drug development (Table 5). Furthermore, in their study, Imamura and colleagues also showed that expression of Ki-67 was less in 3D breast cancer cell mass than in 2D, suggesting that the greater G0-dormant subpopulation was responsible for drug resistance in 3D culture.

Many studies have shown that the breast cancer cell population with phenotype CD44⁺CD24⁻ possesses higher tolerability to chemotherapy, hormone therapy, and radiotherapy¹⁶⁻²¹. Thus, for the drug screening in our study, these 4 breast cancer cell lines were suitable for our evaluations: MCF-7, CD44⁺CD24⁻ MCF-7, VN9, CD44⁺CD24⁻ VN9. Moreover, a promising outcome from our study is the identification of 10 extracts which have a more sensitive effect on the 3D culture model than the 2D culture model. These 10 extracts include: E10, E12, E15, E18, E22, E26, E30, E35, E36, and E42. These could be suitable candidates for the next steps towards developing drugs that target the hypoxic region in breast cancer. Therapies targeting cancer cells in areas of hypoxia and studies to discern mechanisms have garnered increased interest for cancer treatment. Hypoxia-related mechanisms such as overexpression of hypoxia-inducible factor (HIF) are also important avenues of research. Inhibiting HIF activity and changing the molecules involved in HIF offer hope for identifying molecular targets to inhibit tumor growth or even completely halt growth²². HIF-1 also induces an increase in adenosine 2B receptor expression, thereby promoting the enrichment of breast cancer stem cells by activating protein kinase C-δ²³. Therefore, in the study herein, it was shown that the use of a 3D model of breast cancer cell culture for drug screening reflects a huge difference in drug resistance and drug sensitivity when compared to the 2D culture model. The matrigel 3D culture model is significant for screening compounds related to hypoxia-based therapy for breast cancer.

CONCLUSION

Medium-throughput screening on breast cancer cell models MCF-7, CD44⁺CD24⁻ MCF-7, VN9, and CD44⁺CD24⁻ VN9, in 2D and 3D culture, with 34 extracts showed that resistance to these extracts occurred when cancer cells were cultured in 3D. Resistance to extracts also manifested in the CD44⁺CD24⁻ cell populations (*i.e.* CSC populations). There were 12/34 and 7/34 extracts which affected MCF-7 and CD44⁺CD24⁻ MCF-7 cells, respectively. For the Vietnamese breast cancer cell line

Table 7: The IC₅₀ values of 34 extracts on CD44⁺CD24⁻ VN9 breast cancer cell line

Extracts	IC ₅₀ values (μg/mL)		Extracts	IC ₅₀ values (μg/mL)	
	2D model	3D model		2D model	3D model
E4	38.15	116.8	E25	292.7	2456
E7	69.24	74.54	E27	114.4	402.6
E8	112.8	255.3	E28	108.6	793.3
E9	118	249.6	E30	915.5	1218
E10	74.13	104	E31	67.14	480.1
E11	59.78	475	E32	76.9	479.4
E12	73.57	252.2	E35	99.37	738.9
E13	426.4	1107	E36	364.7	1855
E14	68.61	442.8	E37	119.1	333.4
E15	236	1296	E38	160.5	1022
E16	56.12	229.6	E39	73.18	362.4
E17	27.7	162.5	E40	137.5	992.6
E18	340.2	144.8	E41	372.8	790.6
E19	47.05	685.8	E42	146.6	515
E20	38.34	315.4	E43	126.1	301.5
E21	30.58	342.5	E45	39.07	90.3
E22	777.9	92.74	E46	90.46	193

Abbreviation: IC₅₀: half inhibitory concentration

(VN9), there were 5/34 and 6/34 extracts which affected the VN9 and CD44⁺CD24⁻ VN9 cells, respectively. Overall, our study results indicated 10 potential candidates for future drug development targeting hypoxia in breast cancer.

ABBREVIATIONS

Dox: Doxorubicin

HIF: Hypoxia-Inducible Factor

TPZ: Tirapazamine

VN9: Vietnamese breast cancer cell line #9

CONFLICT OF INTEREST

The authors declare that there is no conflict of interests regarding the publication of this article.

AUTHOR CONTRIBUTIONS

Nhan Phan designed the project and carried out the experiments. Khuong Pham contributed to feasibility experiments. Mai Nguyen provided the extract. Nhan Phan analyzed the data and wrote the paper with contributions from all authors. Phuc Pham, Kiet Truong

and Ngoc Phan suggested the idea, corrected the scientific matters, english wording and review all paper.

ACKNOWLEDGMENTS

This work was supported by the Vietnam National University, Ho Chi Minh City, Vietnam, under grant number A2015-18-01.

REFERENCES

1. Futamura Y, Yamamoto K, Osada H. Phenotypic screening meets natural products in drug discovery. *Biosci Biotechnol Biochem.* 2017;81(1):28–31. PMID: [27885937](https://pubmed.ncbi.nlm.nih.gov/27885937/). Available from: <https://doi.org/10.1080/09168451.2016.1248365>.
2. Alexandrov V, Brunner D, Hanania T, Leahy E. High-throughput analysis of behavior for drug discovery. *Eur J Pharmacol.* 2015;750(89):82. PMID: [25592319](https://pubmed.ncbi.nlm.nih.gov/25592319/). Available from: <https://doi.org/10.1016/j.ejphar.2014.11.047>.
3. Mullard A. Microfluidics platform lowers barrier to drug combination screening. *Nat Rev Drug Discov.* 2018;17(10):691–692. PMID: [30270346](https://pubmed.ncbi.nlm.nih.gov/30270346/). Available from: <https://doi.org/10.1038/nrd.2018.161>.
4. Verjans ET, Doijen J, Luyten W, Landuyt B, Schoofs L. Three-dimensional cell culture models for anticancer drug screening: Worth the effort? *J Cell Physiol.* 2018;233(4):2993–3003. PMID: [28618001](https://pubmed.ncbi.nlm.nih.gov/28618001/). Available from: <https://doi.org/10.1002/jcp.26052>.
5. Haycock JW. 3D cell culture: a review of current approaches and techniques. *Methods Mol Biol.* 2011;2011(695):1–15.

- PMID: 21042962. Available from: https://doi.org/10.1007/978-1-60761-984-0_1.
6. Breslin S, O'Driscoll L. Three-dimensional cell culture: the missing link in drug discovery. *Drug Discov Today*. 2013;18(5-6):240–249. PMID: 23073387. Available from: <https://doi.org/10.1016/j.drudis.2012.10.003>.
 7. Imamura Y, Mukohara Y, Shimono T, Funakoshi Y, Chayahara Y, Toyoda N, et al. Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer. *Oncol Rep*. 2015;33(4):1837–1843. PMID: 25634491. Available from: <https://doi.org/10.3892/or.2015.3767>.
 8. Abe-Fukasawa N, Otsuka K, Aihara A, Itasaki N, Nishino T. Novel 3D Liquid Cell Culture Method for Anchorage-independent Cell Growth, Cell Imaging and Automated Drug Screening. *Sci Rep*. 2018;8(1):3627. PMID: 29483620. Available from: <https://doi.org/10.1038/s41598-018-21950-5>.
 9. Mittler F, Obeid P, Rulina AV, Haguët V, Gidrol X, Balakirev MY. High-Content Monitoring of Drug Effects in a 3D Spheroid Model. *Front Oncol*. 2017;(7):293. PMID: 29322028. Available from: <https://doi.org/10.3389/fonc.2017.00293>.
 10. Eder T, Eder IE. 3D Hanging Drop Culture to Establish Prostate Cancer Organoids. *Methods Mol Biol*. 2017;(1612):167–175. PMID: 28634942. Available from: https://doi.org/10.1007/978-1-4939-7021-6_12.
 11. Nguyen-Ngoc KV, Shamir ER, Huebner RJ, Beck JN, Cheung KJ, Ewald AJ. 3D culture assays of murine mammary branching morphogenesis and epithelial invasion. *Methods Mol Biol*. 2015;p. 135–162. PMID: 25245692. Available from: https://doi.org/10.1007/978-1-4939-1164-6_10.
 12. Shin HS, Hong HJ, Koh WG, Lim JY. Organotypic 3D Culture in Nanoscaffold Microwells Supports Salivary Gland Stem-Cell-Based Organization. *ACS Biomater Sci Eng*. 2018;4(12):4311–4320. PMID: 30591951. Available from: <https://doi.org/10.1021/acsbomaterials.8b00894>.
 13. Dolega ME, Abeille F, Picollet-D'hahan N, Gidrol X. Controlled 3D culture in Matrigel microbeads to analyze clonal acinar development. *Biomaterials*. 2015;p. 347–357. PMID: 25818441. Available from: <https://doi.org/10.1016/j.biomaterials.2015.02.042>.
 14. Kleinman HK, Martin GR. Matrigel: basement membrane matrix with biological activity. *Seminars in cancer biology*. 2005;15(5):378–386. PMID: 15975825. Available from: <https://doi.org/10.1016/j.semcancer.2005.05.004>.
 15. Lee JM, Mhawech-Fauceglia P, Lee N, Parsanian LC, Lin YG, Gayther SA, et al. A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro. *Lab Invest*. 2013;93(5):528–42. PMID: 23459371. Available from: <https://doi.org/10.1038/labinvest.2013.41>.
 16. Palomeras S, Ruiz-Martínez S, Puig T. Targeting Breast Cancer Stem Cells to Overcome Treatment Resistance. *Molecules*. 2018;23(9). PMID: 30200262. Available from: <https://doi.org/10.3390/molecules23092193>.
 17. Sun H, Jia J, Wang X, Ma B, Di L, Song G, et al. CD44+/CD24– breast cancer cells isolated from MCF-7 cultures exhibit enhanced angiogenic properties. *Clin Transl Oncol*. 2013;15(1). PMID: 22855175. Available from: <https://doi.org/10.1007/s12094-012-0891-2>.
 18. Deng X, Apple S, Zhao H, Song J, Lee M, Luo W, et al. CD24 Expression and differential resistance to chemotherapy in triple-negative breast cancer. *Oncotarget*. 2017;8(24):38294–38308. PMID: 28418843. Available from: <https://doi.org/10.18632/oncotarget.16203>.
 19. Rodriguez CE, Berardi DE, Abrigo M, Todaro LB, de Kier Joffé EDB, Fiszman GL. Breast cancer stem cells are involved in Trastuzumab resistance through the HER2 modulation in 3D culture. *J Cell Biochem*. 2018;119(2):1381–1391. PMID: 28722778. Available from: <https://doi.org/10.1002/jcb.26298>.
 20. Chekhun VF, Lukianova NY, Chekhun SV, Bezdienieznykh NO, Zadvorniy TV, Borikun TV, et al. Association of CD44(+)/CD24(-/low) with markers of aggressiveness and plasticity of cell lines and tumors of patients with breast cancer. *Exp Oncol*. 2017;39(3):203–211. Available from: [https://doi.org/10.31768/2312-8852.2017.39\(3\):203-211](https://doi.org/10.31768/2312-8852.2017.39(3):203-211).
 21. Uchiumi K, Tsuboi K, Sato N, Ito T, Hirakawa H, Niwa T, et al. Cancer stem-like properties of hormonal therapy-resistant breast cancer cells. *Breast Cancer*. 2019;26(4):459–470. PMID: 30610551. Available from: <https://doi.org/10.1007/s12282-018-00944-1>.
 22. Badowska-Kozakiewicz AM, Budzik MP, Przybylski J. Hypoxia in breast cancer. *Pol J Pathol*. 2015;66(4):337–346. PMID: 27003764. Available from: <https://doi.org/10.5114/pjp.2015.57245>.
 23. Lan J, Lu H, Samanta D, Salman S, Lu Y, Semenza GL. Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment. *Proc Natl Acad Sci U S A*;115(41):E9640–e9648. PMID: 30242135. Available from: <https://doi.org/10.1073/pnas.1809695115>.